E-ISSN 2218-6050 | ISSN 2226-4485
 

Original Article


Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy

Curtis Wells Dewey, Mark Rishniw, Kasie Sakovitch.


Cited By:2

Abstract
Background: Idiopathic or genetic epilepsy commonly affects dogs; affected dogs are often refractory to anti-seizure drug therapy. Felbamate is an anti-seizure drug with established pharmacokinetic and safety data for dogs, but little published evidence of efficacy for managing generalized seizures in this species.
Aim: The purpose of this retrospective case series was to evaluate the clinical efficacy and tolerability of oral felbamate in 6 presumptive epileptic dogs experiencing generalized seizures.
Methods: Medical records from 6 dogs with presumptive idiopathic/genetic epilepsy manifesting as generalized seizure activity, for which oral felbamate was used as an add-on treatment, were reviewed. The number of seizures recorded for the three-month period immediately before instituting felbamate was recorded for each dog. Short-term (3 months) and long-term (6 months or greater) seizure frequency post-felbamate therapy was recorded for each dog and compared with baseline.
Results: Overall, dogs experienced a reduction (82%) in seizures after adding felbamate in the short-term, with 5/6 dogs (83%) classified as responders (50% or greater reduction in seizures) and 3/6 dogs (50%) attaining seizure-free status. Mean and median long-term follow-up times were 13 and 11 months, respectively (range: 6 to 23 months). Four of the 6 dogs (67%) remained drug responders at final follow-up, with an average seizure reduction of 98%, 2 of which remained seizure free at 8 and 21 months. Two dogs (33%) experienced increased seizure activity during long-term follow-up (12 and 23 months) and were considered non-responders. The non-responder dogs had an average long-term seizure reduction of 33%. No dog experienced any obvious adverse effects associated with felbamate administration. However, one dog not included in the analysis because of insufficient (<3 month) post-felbamate follow-up, was weaned off felbamate because of suspected hepatotoxicity.
Conclusion: Our preliminary investigation suggests that oral felbamate might show promise as an add-on drug for epileptic dogs experiencing generalized seizures resistant to drug therapy. These results warrant more controlled, prospective investigation into felbamate as a therapeutic agent for canine epilepsy.

Key words: Canine, Seizures, Brain, Felbamate


 
ARTICLE TOOLS
Abstract
PDF Fulltext
HTML Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Curtis Wells Dewey
Articles by Mark Rishniw
Articles by Kasie Sakovitch
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Dewey CW, Rishniw M, Sakovitch K, . Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. Open Vet J. 2022; 12(4): 445-450. doi:10.5455/OVJ.2022.v12.i4.5


Web Style

Dewey CW, Rishniw M, Sakovitch K, . Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. https://www.openveterinaryjournal.com/?mno=99099 [Access: February 28, 2024]. doi:10.5455/OVJ.2022.v12.i4.5


AMA (American Medical Association) Style

Dewey CW, Rishniw M, Sakovitch K, . Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. Open Vet J. 2022; 12(4): 445-450. doi:10.5455/OVJ.2022.v12.i4.5



Vancouver/ICMJE Style

Dewey CW, Rishniw M, Sakovitch K, . Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. Open Vet J. (2022), [cited February 28, 2024]; 12(4): 445-450. doi:10.5455/OVJ.2022.v12.i4.5



Harvard Style

Dewey, C. W., Rishniw, M., Sakovitch, K. & (2022) Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. Open Vet J, 12 (4), 445-450. doi:10.5455/OVJ.2022.v12.i4.5



Turabian Style

Dewey, Curtis Wells, Mark Rishniw, Kasie Sakovitch, and . 2022. Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. Open Veterinary Journal, 12 (4), 445-450. doi:10.5455/OVJ.2022.v12.i4.5



Chicago Style

Dewey, Curtis Wells, Mark Rishniw, Kasie Sakovitch, and . "Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy." Open Veterinary Journal 12 (2022), 445-450. doi:10.5455/OVJ.2022.v12.i4.5



MLA (The Modern Language Association) Style

Dewey, Curtis Wells, Mark Rishniw, Kasie Sakovitch, and . "Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy." Open Veterinary Journal 12.4 (2022), 445-450. Print. doi:10.5455/OVJ.2022.v12.i4.5



APA (American Psychological Association) Style

Dewey, C. W., Rishniw, M., Sakovitch, K. & (2022) Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy. Open Veterinary Journal, 12 (4), 445-450. doi:10.5455/OVJ.2022.v12.i4.5